The asymmetric hydrogenation of a selectively crystallised (E)-4,4-diaryl-3-butenoate with a rhodium-PhanePhos catalyst is described, providing an intermediate to the antidepressant sertraline.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/b301175p | DOI Listing |
Publication Analysis
Top Keywords
asymmetric hydrogenation
8
hydrogenation 44-diaryl-3-butenoate
4
44-diaryl-3-butenoate novel
4
novel approach
4
approach sertraline
4
sertraline asymmetric
4
hydrogenation selectively
4
selectively crystallised
4
crystallised e-44-diaryl-3-butenoate
4
e-44-diaryl-3-butenoate rhodium-phanephos
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!